We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




C-reactive Protein Varies According to Genetic Heritage

By LabMedica International staff writers
Posted on 20 Oct 2010
C-reactive protein is found in the blood and the levels rise in response to inflammation and is linked to a higher risk for heart disease.

Even though high C-reactive protein (CRP) blood levels have been associated with a greater chance of developing heart disease, the link is uncertain if the association is casual. More...
It is synthesized by the liver in response to factors released by adipocytes (fat cells). Scientists are not sure whether the CRP-lowering effects of statins have any health benefits.

In a study, carried out at the University College London (UCL; London, UK), investigators examined data on 221,287 individuals from 89 published studies. The risk cut-off point used was 2 mg/L based on the findings of the US Food and Drug Administration (FDA; Silver Spring, MD, USA) for males over 50 and females over 60 who have one other heart disease risk factor as well as CRP values over the this level.

The scientists found that CRP blood levels vary according to ethnicity, even after such factors as age and body mass index (BMI) has been taken into account. They found the following geometric mean CRP levels according to ancestry: 2.6 mg/L in 18,585 African-Americans; 2.51 mg/L in 5,049 Hispanics; 2.34 mg/L in 1,053 South Asians; 2.03 mg/L in 104,949 Caucasians; and 1.01 mg/L in 39,521 East Asians. The order remained unchanged when the investigators calculated the probability that individuals in each ethnic group would exceed the 2 mg/L CRP threshold at any age. Over 50% of Hispanics and African-Americans were over the 2 mg/L CRP threshold at the age of 50, compared to fewer than half of East Asians. At the age of 60 under 40% of East Asians and nearly two-thirds of African-Americans and Hispanics would likely have a CRP greater than 2 mg/L.

Tina Shah, Ph.D., coauthor of the study, noted that, "The difference in average population CRP values in populations of different ancestry are sufficiently large as to have bearing on clinical management and statin eligibility based on single CRP cut-off point values." The study was published online on September 28, 2010 in Circulation: Cardiovascular Genetics.

Related Links:
University College London
FDA



Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
Automated Clinical Chemistry Analyzer
Envoy 500+
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Graphical Abstract (Morgane Fournier et al., Cell (2026). DOI: 10.1016/j.cell.2026.04.013)

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more

Pathology

view channel
Image: Agilent’s PD-L1 IHC 22C3 pharmDx has received EU certification as a companion diagnostic to identify PD-L1–positive ovarian, fallopian tube, or primary peritoneal carcinoma patients eligible for KEYTRUDA (Photo courtesy of Agilent)

PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers

Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.